Extended Data Fig. 8. PD-L2 blockade eliminates mammary tumors after chemotherapy.
(a) Body weight of PyMT mice during doxorubicin and anti-PD-L2 treatments, corresponding to Fig. 5a. 2-way ANOVA. N = 3 mice for anti-PD-L2 monotherapy, n = 4 for PBS and doxo + IgG groups, n = 5 for doxo + anti-PD-L2. (b) Representative hematoxilin/eosin staining of liver and myocardium of animals treated with anti-PD-L2 (10 mg/kg) (n = 2 mice) or vehicle (PBS, n = 1) every three days for four weeks. Scale bar = 100 μm. (c) Individual replicates (n = 2 mice) of tumor growth curves in PyMT mice treated with doxorubicin and anti-PD-L2, together with blocking antibodies against CD4 (10 mg/kg) and CD8 (10 mg/kg), or the same dose of IgG isotype control, every three days for four weeks.